Vitrolife AB Fourth quarter and full year report, 2024: A strong finish to the year

Rhea-AI Summary

Vitrolife AB reported strong Q4 2024 results with sales reaching SEK 959 million, up 6% in local currencies. Regional performance showed growth of 10% in EMEA and 9% in Americas, while APAC declined 2%. By business area, Consumables grew 12%, Technologies 9%, while Genetics remained flat.

The company's gross margin improved to 61.1% from 56.9%, while EBITDA increased to SEK 337 million with a margin of 35.1%. Net income recovered significantly to SEK 139 million from a loss of SEK 4,179 million, resulting in earnings per share of SEK 1.03.

For full-year 2024, sales reached SEK 3,609 million, showing 4% growth in local currencies. The Board proposed a dividend of SEK 1.10 per share, up from SEK 1.00 in the previous year. Operating cash flow for the year improved to SEK 907 million from SEK 757 million.

Positive

• Q4 sales increased 6% to SEK 959 million
• Q4 gross margin improved to 61.1% from 56.9%
• Q4 EBITDA margin increased to 35.1% from 32.5%
• Operating cash flow improved to SEK 907 million from SEK 757 million
• Proposed dividend increased to SEK 1.10 from SEK 1.00 per share
• Strong recovery in net income from previous year's losses

Negative

• APAC region showed -2% growth in Q4
• Genetics business area showed 0% growth in Q4
• Genetics segment declined -5% for full year

GOTHENBURG, Sweden, Jan. 30, 2025 /PRNewswire/ -- Fourth quarter            

• Sales of SEK 959 (904) million, an increase of 6% in local currencies and 6% in SEK.           
• Sales per region, in local currencies was +10% in EMEA, +9% in Americas and -2% in APAC.           
• Sales per business area, in local currencies was +12% in Consumables, +9% in Technologies and 0% in Genetics.           
• Gross margin increased to 61.1% (56.9).           
• Operating income before depreciation and amortisation (EBITDA) increased to SEK 337 (294) million, giving an EBITDA margin of 35.1% (32.5).          
• Operating cash flow increased to SEK 268 million (171).           
• Net income was SEK 139 (-4,179) million, resulting in earnings per share before dilution of SEK 1.03 (-30.86) and after dilution of SEK 1.02 (-30.86).           
• Helena Wennerström was appointed acting CFO of Vitrolife AB (publ) effective 3 December 2024.

Full year            

• Sales of SEK 3,609 (3,512) million, an increase of 4% in local currencies and 3% in SEK.           
• Sales per region, in local currencies was +7% in EMEA, +1% in Americas and +5% in APAC.           
• Sales per business area, in local currencies was +10% in Consumables, +16% in Technologies and -5% in Genetics.           
• Gross margin increased to 59.3% (56.3).           
• Operating income before depreciation and amortisation (EBITDA) increased to SEK 1,225 (1,136) million, giving an EBITDA margin of 34.0% (32.3).           
• Operating cash flow increased to SEK 907 million (757).           
• Net income was SEK 514 (-3,851) million, resulting in earnings per share before dilution of SEK 3.79 (-28.44) and after dilution of SEK 3.78 (-28.44).

Dividend           

• The Board to propose to the Annual General Meeting a dividend of SEK 149 (135) million, corresponding to SEK 1.10 (1.00) per share.

Gothenburg, January 30, 2025
VITROLIFE AB (publ)
Bronwyn Brophy O´Connor,
CEO

The information was submitted for publication, through the agency of the contact persons set out above, at 30-01-2025 08:00 CET.

Contact: 
Helena Wennerström, acting CFO, phone: +4670 822 80 86

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

This information was brought to you by Cision http://news.cision.com.

https://news.cision.com/vitrolife-ab--publ-/r/fourth-quarter-and-full-year-report--2024--a-strong-finish-to-the-year,c4098077

The following files are available for download:

https://mb.cision.com/Main/1031/4098077/3235667.pdf

Interim report Q4, 2024: A strong finish to the year

 

View original content:https://www.prnewswire.com/news-releases/vitrolife-ab-fourth-quarter-and-full-year-report-2024-a-strong-finish-to-the-year-302364243.html

SOURCE Vitrolife AB (publ)

FAQ

What was Vitrolife's (VTRLY) Q4 2024 sales performance?

Vitrolife's Q4 2024 sales reached SEK 959 million, representing a 6% increase in both local currencies and SEK.

How did Vitrolife's (VTRLY) regional sales perform in Q4 2024?

In Q4 2024, EMEA sales grew 10%, Americas increased 9%, while APAC declined 2% in local currencies.

What is Vitrolife's (VTRLY) dividend proposal for 2024?

The Board proposed a dividend of SEK 1.10 per share, up from SEK 1.00 in the previous year, totaling SEK 149 million.

How did Vitrolife's (VTRLY) business segments perform in Q4 2024?

In Q4 2024, Consumables grew 12%, Technologies increased 9%, and Genetics showed 0% growth in local currencies.

What was Vitrolife's (VTRLY) EBITDA margin in Q4 2024?

Vitrolife's Q4 2024 EBITDA margin increased to 35.1% from 32.5% in the previous year.